SUZHOU, China, Dec. 30, 2024 — Hangzhou Sino-US Huadong Medicine Co., Ltd. (referred to as “Huadong Medicine“), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (referred to as “SynerK”) have formed a strategic partnership. They will collaboratively develop the siRNA drug SNK-2726, targeting angiotensinogen (AGT) to treat hypertension. Huadong Medicine holds the exclusive option, upon exercise, to develop, register, manufacture, and commercialize the drug in Greater China.
SynerK holds SNK-2726’s intellectual property rights; the drug is in the IND filing preparation phase. The agreement outlines joint development to a specific stage. Huadong Medicine has the exclusive option, with a potential future exercise fee, for exclusive development, registration, production, and commercialization rights in Greater China. Following Huadong Medicine‘s exercise of these rights, SynerK will receive subsequent R&D and sales milestones, plus tiered royalties on net sales after commercialization.
SynerK CEO Dr. Tao Lan stated: “We are thrilled to partner with Huadong Medicine. Huadong Medicine’s ‘scientific research-based and patient-centered’ philosophy aligns with our mission of ‘changing patients’ lives.’ This collaboration showcases the potential of SynerK’s GalNexus siRNA platform. This synergistic effort will accelerate SNK-2726’s development and provide patients with new treatment options.”
Lv Liang, chairman and general manager of Huadong Medicine, commented: “We are delighted to partner with SynerK on the innovative siRNA drug SNK-2726. SynerK possesses novel nucleic acid drug technology platforms with independent intellectual property. Huadong Medicine will leverage its extensive experience in innovative drug R&D and cardiovascular drug commercialization. Through close collaboration, we will accelerate SNK-2726’s development and benefit hypertensive patients.”
About SNK-2726
SNK-2726, with intellectual property rights held by SynerK, is a subcutaneous RNAi drug targeting angiotensinogen (AGT). It’s being developed for hypertension and is in the IND application preparation stage. AGT is a precursor in the renin-angiotensin-aldosterone system (RAAS), primarily produced by the liver. Inhibiting AGT production effectively blocks RAAS activity and lowers blood pressure. Preclinical data showed SNK-2726 potently and durably inhibits AGT synthesis in the liver, leading to sustained blood pressure reduction.
About SynerK
SynerK is a biopharmaceutical company focused on RNA-targeted therapies. It operates in the USA (Boston, MA) and China (Suzhou and Beijing). Its co-founders are industry experts with extensive nucleic acid drug development experience. SynerK aims to become a world-class RNA-targeted therapeutic company, developing first-in-class or best-in-class treatments for challenging diseases.
For more information, please visit:
About Huadong Medicine Co., Ltd.
Huadong Medicine Co., Ltd. (stock code: 000963.SZ), founded in 1993 and headquartered in Hangzhou, Zhejiang, adheres to a ‘scientific research-based and patient-centered’ philosophy. After over 30 years, its business encompasses the entire pharmaceutical industry chain, with four segments: pharmaceuticals, pharmaceutical services, aesthetic medicine, and industrial microbiology. It’s a large-scale, listed pharmaceutical company integrating R&D, production, and distribution. In 2023, it had 40.624 billion yuan in operating income, over 10,000 employees, and extensive commercial reach.
For more information, please visit
SOURCE SynerK